Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Menjugate (Chiron).

D H Jones1

  • 1Intellivax International Inc, Ville St-Laurent, Quebec, Canada. tjones@intellivax.com

Current Opinion in Investigational Drugs (London, England : 2000)
|August 31, 2001
PubMed
Summary
This summary is machine-generated.

Chiron

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Black Hole Spectroscopy and Tests of General Relativity with GW250114.

Physical review letters·2026
Same author

GW250114: Testing Hawking's Area Law and the Kerr Nature of Black Holes.

Physical review letters·2025
Same author

Improving cosmological reach of a gravitational wave observatory using Deep Loop Shaping.

Science (New York, N.Y.)·2025
Same author

SEPN1-related myopathies: clinical course in a large cohort of patients.

Neurology·2011
Same author

Markers for the identification of tumours arising from the neuroectoderm.

Reviews in the neurosciences·2011
Same author

Use of polymerase chain reaction for making recombinant constructs.

Methods in molecular biology (Clifton, N.J.)·2011
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Area of Science:

  • Vaccinology
  • Microbiology
  • Immunology

Background:

  • Meningococcus C infections, caused by Neisseria meningitidis, pose a significant health risk.
  • The development of effective vaccines is crucial for preventing meningococcal disease.

Purpose of the Study:

  • To introduce Menjugate, a novel vaccine developed by Chiron for the prevention of meningococcus C infections.
  • To detail the regulatory approval process and market launch of Menjugate.

Main Methods:

  • Menjugate utilizes CRM-conjugate technology, employing a diphtheria toxoid carrier protein linked to meningitis C-specific antigens.
  • The vaccine is indicated for individuals 12 months and older, with plans for broader age group approvals.

Main Results:

Related Experiment Videos

  • Menjugate received marketing authorization in the UK in March 2000 and in Ireland in August 2000.
  • A vaccination program utilizing Menjugate commenced in the UK in April 2000.

Conclusions:

  • Menjugate represents a significant advancement in the prevention of meningococcal C disease.
  • The vaccine's CRM-conjugate technology holds potential for protecting both infants and adults.